nVision Medical Company
.jpg)
Acquired by Boston Scientific. nVision developed the first and only device cleared by the U.S. Food and Drug Administration to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. Recent studies have confirmed that several major types of ovarian cancer appear to originate from the fallopian tubes.
Total Funding:
$16,405,000
Headquarters:
San Bruno, California, United States
Funding Status:
M&A
Employee Number:
1-10
Estimated Revenue:
$1M to $10M
Last Funding Type:
Series B
Last Funding Date:
2016-07-21
Investors Number:
9
Founded Date:
01-01-2009
Industry:
General Health Care